Overview

A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate and compare the safety and efficacy of two drugs (ADVAGRAF® and PROGRAF® groups) in patients who received renal transplantation.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Korea, Inc.

Treatments:

Tacrolimus